降胆固醇单片复方制剂临床应用中国专家共识
Chinese Expert Consensus on Clinical Application of Single-pill Combination of Cholesterol-lowering Agents
中国医师协会心血管内科医师分会 葛均波
摘要
有效的血脂管理可显著降低动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)负担,但目前我国ASCVD患者血脂管理仍面临血脂达标率低、治疗依从性不佳的现状.越来越多的证据显示,他汀和非他汀类药物组成的单片复方制剂(single-pill combination,SPC)对于提高血脂达标率、改善治疗依从性及预防不良心血管事件具有重要意义.为了规范我国降胆固醇SPC的临床应用,中国医师协会心血管内科医师分会组织国内心血管、脑血管、内分泌及药理学专家共同制定了《降胆固醇单片复方制剂临床应用中国专家共识》.本共识对SPC的临床应用优势及临床研究进行了阐述,并制定了ASCVD防治血脂管理路径,对SPC的适用人群、用法用量、不良反应处理等给出了明确的指导意见.
Abstract
Effective lipid management can significantly reduce the burden of atherosclerotic cardiovascular disease(ASCVD).However,lipid management for ASCVD prevention and treatment in China still faces the challenges of low attainment rate and poor adherence.An increasing body of evidence suggests that a single-pill combination(SPC)of statin and non-statin agents is effective for improving blood lipid control rate,improving treatment adherence,and reducing adverse cardiovascular events.To standardize the clinical application of the cholesterol-lowering single-pill combination therapy in China,the"Chinese Expert Consensus on Clinical Application of Single-pill Combination of Cholesterol-lowering Agents"was developed with the efforts of a number of domestic experts from cardiovascular,cerebrovascular,endocrinological,and pharmacological fields.The advantages in clinical application and clinical research of cholesterol-lowering SPC were elaborated in this consensus,and the clinical pathway of lipid management for ASCVD prevention and treatment was formulated.Meanwhile,suggestions on the applicable population,usage and dosage,and management of adverse events of cholesterol-lowering SPC were provided.
关键词
单片复方制剂/动脉粥样硬化心血管疾病/血脂管理/胆固醇/联合治疗Key words
single-pill combination/atherosclerotic cardiovascular disease/blood lipid management/cholesterol/combination therapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据